Thermo Fisher Scientific Inc

Valuation Analysis

About the Company

Thermo Fisher Scientific Inc en bref

Thermo Fisher Scientific Inc (TMO) is currently trading at 406,02 € with a market capitalization of 150,9 Md €. The trailing P/E ratio stands at 25.59x, with a forward P/E of 17.09x. The 52-week range spans from 340,42 € to 561,41 €; the current price is 27.7% below the yearly high. Year-over-year revenue growth stands at +6.2%. The net profit margin stands at 15.15%.

💰 Dividende

Thermo Fisher Scientific Inc pays an annual dividend of 1,64 € per share, representing a yield of 0.4%. The payout ratio stands at 9.68%.

📊 Avis des analystes

26 analystes évaluent Thermo Fisher Scientific Inc (TMO) au consensus : Acheter. L'objectif de cours moyen est de 522,35 €, soit un potentiel de +28.65% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 427,16 € à 653,82 €.

Thermo Fisher Scientific Inc : la thèse d'investissement en détail

Thermo Fisher Scientific Inc (TMO) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

The combination of a 40.93% gross margin and 17.89% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Free cash flow is positive and net margins stand at 15.15%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions. Wall Street consensus sits at Buy with an average price target implying roughly 28.65% upside from current levels — analyst sentiment is firmly constructive.

À surveiller

• The forward P/E of 17.09x is meaningfully below the trailing 25.59x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 28.65% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Thermo Fisher Scientific Inc?

Compare top-rated brokers — low fees, trusted providers, fully regulated.